Yoshinori Kakutani

Yoshinori Kakutani

Auto-generated profile, based on publicly available information

Yoshinori Kakutani

Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
MMMasako Miyashima
Masako Miyashima
TSTetsuo Shoji
Tetsuo Shoji
YKYoshinori Kakutani
Yoshinori Kakutani
YYYuko Yamazaki
Yuko Yamazaki
AOAkinobu Ochi
Akinobu Ochi
MEMasanori Emoto
Masanori Emoto
Aim: Inter-arm blood pressure difference (IAD) is known to be associated with a composite of cardiovascular disease (CVD) and with CVD risk factors. However, only limited information is available regarding the contribution of diabetes mellitus to IAD and the association of IAD with individual CVDs, such as coronary artery disease (CAD), stroke, and peripheral artery disease (PAD). Methods: We addressed these issues in this cross-sectional study of 2580 participants who had simultaneous blood pressure measurements in both arms using an automated device. Results: Compared with 1,264 nondiabetic subjects, 1316 patients with diabetes mellitus had a greater IAD (P=0.01) and a higher prevalence of IAD of ≥ 10 mmHg (8.4% vs. 5.4%, P=0.002). However, such difference was not significant after the adjustment for potential confounders. Among CAD, stroke, and PAD, only PAD was significantly associated with IAD in a model adjusted for the CVD risk factors. Age was found to modify the association between IAD and PAD, with the association being more prominent in the younger subgroup. Conclusion: Thus, diabetes mellitus itself was not an independent factor associated with IAD. A larger IAD was preferentially associated with the presence of PAD, and this association was modified by age.

1 July 2024 in Diabetes & Vascular Disease Research
Verified
Journal Article
Open access
YKYoshinori Kakutani
Yoshinori Kakutani
TMTomoaki Morioka
Tomoaki Morioka
YYYuko Yamazaki
Yuko Yamazaki
AOAkinobu Ochi
Akinobu Ochi
SFShinya Fukumoto
Shinya Fukumoto
MEMasanori Emoto
Masanori Emoto
Introduction: Syndecan (SDC)-1 is a transmembrane heparan sulfate proteoglycan and is a major component of endothelial glycocalyx (EG). This study aimed to investigate the association of serum SDC-1 concentration as a marker of EG degradation with albuminuria in type 2 diabetes. Methods: We included 370 patients with type 2 diabetes and 219 individuals with no diabetes. The individuals with estimate glomerular filtration rate <30 mL/min/1.73 m2 were excluded. Results: Serum SDC-1 concentration was higher in type 2 diabetes than in no diabetes. The presence of diabetes was independently associated with log [SDC-1] in multivariate analysis. In type 2 diabetes, serum SDC-1 concentration was correlated with log [urinary albumin-to-creatinine ratio (ACR)]. Moreover, log [SDC-1] was an independent determinant of log [ACR] after adjustment for known risk factors of albuminuria. Conclusions: Serum SDC-1 concentration was higher in patients with type 2 diabetes compared to individuals with no diabetes and an independent determinant of ACR. This study implicates the role of the EG degradation in albuminuria in type 2 diabetes.

30 July 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
AKAtsushi Kitamura
Atsushi Kitamura
MKMasafumi kurajoh
Masafumi kurajoh
YMYuya Miki
Yuya Miki
YKYoshinori Kakutani
Yoshinori Kakutani
YYYuko Yamazaki
Yuko Yamazaki
MEMasanori Emoto
Masanori Emoto
Aim/Introduction: Xanthine oxidoreductase (XOR) inhibitor treatment, which reduces reactive oxygen species (ROS) production and increases adenosine triphosphate (ATP) synthesis, has been reported to improve glycemic control. The possible protective effects of XOR inhibitor treatment on insulin secretory capacity were investigated in patients with type 2 diabetes.Materials and Methods: This retrospective cross‐sectional study included 428 patients with type 2 diabetes. Insulin secretory capacity was assessed based on fasting serum C‐peptide concentration (CPR) and C‐peptide index (CPI) in all subjects, while insulin resistance in non‐insulin users (n = 312) was determined using the homeostasis model assessment of insulin resistance (HOMA‐IR) index.Results: Median values for CPR and CPI in all subjects were 2.4 ng/mL and 1.5, respectively, while that for HOMA‐IR in non‐insulin users was 3.2. The XOR inhibitor users (n = 72) had significantly (P < 0.001) higher CPR and CPI levels than non‐users (n = 356). Multivariable regression analyses showed XOR inhibitor use was positively associated with CPR (β = 0.153, P = 0.001) and CPI (β = 0.144, P = 0.001). Similar results were observed in propensity score analyses. In subgroup analyses of patients with a preserved estimated glomerular filtration rate (≥60 mL/min/1.73 m2) and non‐insulin users, these associations remained significant. Furthermore, the associations were significant in patients with lower (≤6.0 mg/dL) but not with higher (>6.0 mg/dL) uric acid levels (P for interaction <0.05). On the other hand, XOR inhibitor use showed no significant association with HOMA‐IR.Conclusions: The results of XOR inhibitor treatment, especially a sufficient reduction in serum uric acid level, may provide protective effects on insulin secretory capacity in patients with type 2 diabetes.

16 February 2026 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
YKYoshinori Kakutani
Yoshinori Kakutani
TMTomoaki Morioka
Tomoaki Morioka
SMShoko Miyamoto
Shoko Miyamoto
YNYuka Natsuki
Yuka Natsuki
YMYuya Miki
Yuya Miki
MEMasanori Emoto
Masanori Emoto
Objective: Real-time continuous glucose monitoring (CGM) systems are beneficial for patients with diabetes by providing a comprehensive assessment of glycemic status and reducing hypoglycemia. However, their performance in patients with both diabetes and chronic kidney disease (CKD) during hospitalization remains unclear. This study aimed to evaluate the accuracy of real-time CGM in hospitalized patients with diabetes and CKD. Research Design and Methods: We conducted a prospective observational study including 52 patients with diabetes after excluding those with acute kidney injury, active glomerulonephritis, requiring intensive care, or undergoing hemodialysis. Participants were categorized by estimated glomerular filtration rate (eGFR, mL/min/1.73 m 2 ) into G1-2 (≥60), G3 (30–59), and G4-5 (<30). Capillary glucose values were measured with a validated point-of-care (POC) device and paired with corresponding real-time CGM (G6, Dexcom) readings. Accuracy was assessed by mean absolute relative difference (MARD), correlation analyses, Bland–Altman plots, and consensus error grid (CEG) analyses. Results: A total of 1603 paired glucose values were analyzed, including 752 in G1/2, 571 in G3, and 280 in G4/5. CGM and POC glucose were strongly correlated ( r = 0.91, P < 0.001). The overall MARD was 17.0%, with group-specific values of 19.4% in G1/2, 15.5% in G3, and 13.5% in G4/5 ( P < 0.001). Bland–Altman plots showed smaller bias and narrower limits of agreement in advanced CKD. CEG analyses demonstrated high agreement, with >99% of values within clinically acceptable zones. Conclusions: The Dexcom G6 demonstrated reliable accuracy in hospitalized patients with diabetes and CKD, with better performance in advanced CKD. These findings support its clinical utility in this population.